Abstract: Objective：To study the efficiency and toxicity on the neoadjuvant second- line vinorelbine and gemcitabine(GN) in the treatment of locally advanced breast cancer (LABC) resistant to anthracyclines and taxanes-containing regimen. Methods：Twenty-six LABC patients who failed to achieve response to 2-4 cycles of acombination of docetaxel, doxorubicin, and cyclophosphamide (TAC) were enrolled. Vinorelbine and gemcitabine were given at a dose of 25mg /m2 and 1000mg / m2 by intravenous injection at day 1, 8 respectively, repeated every 21 days. Response was assessed every two cycles. Stable and progressed patients were operated upon while responding cases continue. All patients received 2-6 cycles of chemotherapy, then underwent adequate surgery 2 weeks later. Results Among these 26 patients, the Clinical response rate was 46.% with 2 CR, 10 PR. Breast conservative surgery (BCS) became possible in 4 cases (15%).The most common toxicities were neutropenia, thrombocytopenia, nausea, vomiting , mucositis and neuropathy. Conclusion：Vinorelbine and gemcitabine(GN) combination can be used as second-line neoadjuvant chemotherapy in LABC patients who resistant to anthracyclines and taxanes-containing regimen. Clinical responses was effective and toxicities were tolerable.